SCM
ENTA icon

Sterling Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Sterling Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4K Sell
903
-669
-43% -$8.97K ﹤0.01% 2301
2025
Q4 		$24.8K Buy
1,572
+181
+13% +$2.3K ﹤0.01% 2111
2025
Q3 		$16.6K Buy
1,391
+853
+159% +$6.82K ﹤0.01% 2231
2025
Q2 		$4.07K Buy
538
+177
+49% +$1.06K ﹤0.01% 2624
2025
Q1 		$1.99K Sell
361
-321
-47% -$1.98K ﹤0.01% 2607
2024
Q4 		$3.92K Buy
682
+618
+966% +$5.92K ﹤0.01% 2560
2024
Q3 		$663 Buy
+64
New +$837 ﹤0.01% 2740

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sterling Capital Management's ENTA Position: Q1 2026 in Review

Sterling Capital Management reduced its Enanta Pharmaceuticals (ENTA) stake by 43% in Q1 2026, selling an estimated $8.97K and leaving 903 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Sterling Capital Management first reported a position in ENTA in Q3 2024 and has held it in 7 quarters since. The position peaked at $24.8K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Sterling Capital Management held 903 shares of Enanta Pharmaceuticals worth $11.4K as of Q1 2026.
  • Sterling Capital Management sold 669 Enanta Pharmaceuticals shares in Q1 2026, an estimated $8.97K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2301 holding.
  • Sterling Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Enanta Pharmaceuticals position peaked at $24.8K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.